Pre-revenue medical device company still in human-trial stage; valuation driven by regulatory/clinical milestones and Musk-brand premium rather than fundamentals. The gap between the primary Series E price ($9.6B) and the Series E-LV/secondary mark ($28.6B) signals a thin, sentiment-driven secondary market. Oman's sovereign wealth fund (Oman Investment Authority) confirmed a Neuralink investment around May 2026 (amount and valuation undisclosed) -- part of a pattern of Gulf sovereign funds backing Musk companies. Widely-circulated claims of a '$12-15B next round expected in 2026' and a second '$650M Series E closed April 2026' could not be traced to any real article and are almost certainly aggregator artifacts (the latter likely a garbled restatement of the actual June 2025 round) -- not included here. Neuralink is explicitly separate from the SpaceX-xAI merger targeting a combined ~$1.25T IPO.
| Round | Date | Valuation | Lead |
|---|---|---|---|
| Series D | 2023-08-01 | $3.5B | Founders Fund |
| Series E-LV | 2025-06-01 | $28.6B+717% | Not applicable -- this is a Forge Global secondary-market price mark aggregating private secondary trades, not a VC-led primary tranche with a term sheet or a named lead |
| Series E | 2025-06-02 | $9.6B-66% | No single lead -- a syndicate of ARK Invest, Founders Fund, Sequoia Capital, and Thrive Capital (also DFJ Growth, G42, Human Capital, Lightspeed, QIA, Valor Equity Partners, Vy Capital) |
No upcoming rounds currently reported.
| Status | S-1 Not Filed |
|---|---|
| Notes | No Neuralink-specific IPO timeline reported by any tier-1 outlet. Explicitly not part of the SpaceX-xAI merger targeting a combined ~$1.25T IPO around mid-2026. |
| Source | CNBC, Feb 2 2026 (SpaceX/xAI merger); no primary Neuralink-specific IPO source found |
These are cited news signals only, not a PrePost prediction — year/valuation forecasting is on the roadmap but not live yet.
Transparent, formula-based composite (not machine-learned) of five signals: raise velocity, round acceleration, secondary premium/discount vs. the last primary round, up-round streak, and freshness of the last known mark.